Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Bioorg Med Chem Lett ; 21(14): 4363-5, 2011 Jul 15.
Article in English | MEDLINE | ID: mdl-21664132

ABSTRACT

The preparation and characterization of a series of thiophenyl oxime phosphonate beta-lactamase inhibitors is described. A number of these analogs were potent and selective inhibitors of class C beta-lactamases from Pseudomonas aeruginosa and Enterobacter cloacae. Compounds 3b and 7 reduced the MIC of imipenem against an AmpC expressing strain of imipenem-resistant P. aeruginosa. A number of the title compounds retained micromolar potency against the class D OXA-40 beta-lactamase from Acinetobacter baumannii and at high concentrations compound 3b was shown to reduce the MIC of imipenem against a highly imipenem-resistant strain of A. baumanii expressing the OXA-40 beta-lactamase. In mice compound 3b exhibited phamacokinetics similar to imipenem.


Subject(s)
Acinetobacter baumannii/drug effects , Anti-Bacterial Agents/chemistry , Enzyme Inhibitors/chemistry , Organophosphonates/chemistry , Oximes/chemistry , Pseudomonas aeruginosa/drug effects , beta-Lactamase Inhibitors , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/pharmacology , Drug Resistance, Bacterial , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacology , Imipenem/pharmacology , Microbial Sensitivity Tests , Organophosphonates/chemical synthesis , Organophosphonates/pharmacology , Oximes/chemical synthesis , Oximes/pharmacology , Thiophenes/chemistry , beta-Lactamases/metabolism
2.
Bioorg Med Chem Lett ; 20(8): 2622-4, 2010 Apr 15.
Article in English | MEDLINE | ID: mdl-20299220

ABSTRACT

4,7-Dichloro-1-benzothien-2-yl sulfonylaminomethyl boronic acid (DSABA, Compound I) was discovered as the first boronic acid-based class D beta-lactamase inhibitor. It exhibited an IC(50) of 5.6 microM against OXA-40. The compound also inhibited class A and C beta-lactamases with sub to low microM IC(50), and synergized with imipenem against Acinetobacter baumannii.


Subject(s)
Anti-Bacterial Agents/pharmacology , Boronic Acids/pharmacology , Enzyme Inhibitors/pharmacology , beta-Lactamase Inhibitors , Acinetobacter baumannii/drug effects , Anti-Bacterial Agents/chemistry , Boronic Acids/chemistry , Enzyme Inhibitors/chemistry , Inhibitory Concentration 50 , Microbial Sensitivity Tests
3.
Chem Res Toxicol ; 15(7): 907-14, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12119000

ABSTRACT

Raloxifene is a selective estrogen receptor modulator which is effective in the treatment of osteoporosis in postmenopausal women. We report herein that cytochrome P450 (P450)3A4 is inhibited by raloxifene in human liver microsomal incubations. The nature of the inhibition was irreversible and was NADPH- and preincubation time-dependent, with K(I) and k(inact) values estimated at 9.9 microM and 0.16 min(-1), respectively. The observed loss of P450 3A4 activity was attenuated partially by glutathione (GSH), implying the involvement of a reactive metabolite(s) in the inactivation process. Subsequently, GSH adducts of raloxifene were identified in incubations with human liver microsomes; substitution with GSH occurred at the 5- or 7-position of the benzothiophene moiety or at the 3'-position of the phenol ring, with the 7-glutathionyl derivative being most abundant based on LC/MS and NMR analyses. These adducts are postulated to derive from addition of GSH to raloxifene arene oxides followed by dehydration and aromatization. Alternatively, raloxifene may be oxidized to an extended quinone intermediate, which then is trapped by GSH conjugation. The bioactivation of raloxifene most likely is catalyzed by P450 3A4, since the formation of GSH adducts was almost abolished when liver microsomes were pretreated with ketoconazole or with an inhibitory anti-P450 3A4 IgG. The GSH adducts also were detected in incubations of raloxifene with rat or human hepatocytes, while the corresponding N-acetylcysteine adducts were identified in the bile and urine from rats treated orally with the drug at 5 mg/kg. Taken together, these data indicate that P450 3A4-mediated bioactivation of raloxifene in vitro is accompanied by loss of enzyme activity. The significance of these findings with respect to the clinical use of raloxifene remains to be determined.


Subject(s)
Cytochrome P-450 Enzyme Inhibitors , Enzyme Inhibitors/metabolism , Raloxifene Hydrochloride/metabolism , Selective Estrogen Receptor Modulators/metabolism , Sulfhydryl Compounds/chemistry , Acetylcysteine/chemistry , Animals , Cytochrome P-450 CYP3A , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Female , Gas Chromatography-Mass Spectrometry , Glutathione/chemistry , Hepatocytes/enzymology , Hepatocytes/metabolism , Humans , Magnetic Resonance Spectroscopy , Male , Microsomes, Liver/enzymology , Microsomes, Liver/metabolism , Oxidation-Reduction , Raloxifene Hydrochloride/chemistry , Raloxifene Hydrochloride/pharmacology , Rats , Rats, Sprague-Dawley , Selective Estrogen Receptor Modulators/chemistry , Selective Estrogen Receptor Modulators/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...